Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference
Rhea-AI Summary
Supernus Pharmaceuticals (Nasdaq: SUPN) announced that Jack A. Khattar, President and CEO, will present at the Bank of America Securities 2025 CNS Therapeutics Virtual Conference on Monday, December 8, 2025 at 3:20 p.m. ET.
Investors can request meetings through the Bank of America conference coordinator. A live audio webcast will be available via the company’s Events & Presentations page on www.supernus.com, and an archived replay will remain on the site for 60 days after the conference.
Positive
- None.
Negative
- None.
News Market Reaction – SUPN
In the Dec 4 session, SUPN gained 0.76%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 09 | Regulatory approval | Positive | -3.7% | Health Canada approval for ZURZUVAE in postpartum depression. |
| Dec 03 | Conference participation | Neutral | +0.2% | Announcement of Bank of America CNS conference presentation. |
| Nov 21 | Conference participation | Neutral | -0.4% | Participation in Piper Sandler healthcare conference fireside chat. |
| Nov 12 | Conference participation | Neutral | -0.4% | Jefferies Global Healthcare Conference fireside chat in London. |
| Nov 04 | Quarterly earnings | Positive | +2.3% | Q3 2025 revenue growth and raised full-year guidance post-Sage deal. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent conference announcements for SUPN have coincided with relatively small next-day price moves, while the Q3 earnings update with raised guidance saw a more notable positive reaction.
Over the last several months, Supernus has mixed routine conference participation news with more material corporate developments. The company reported Q3 2025 revenue of $192.1M and raised full-year guidance following the Sage acquisition, which generated collaboration revenue from ZURZUVAE. Subsequent filings detailed the Sage deal terms and ONAPGO supply constraints. Against this backdrop, today’s Bank of America CNS conference appearance continues a pattern of active investor and conference engagement.
Key Terms
central nervous system (CNS) medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKVILLE, Md., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will present at the Bank of America Securities 2025 CNS Therapeutics Virtual Conference on Monday, December 8, 2025, at 3:20 p.m. ET.
Investors interested in arranging a meeting with company management during the conference should contact the Bank of America conference coordinator. A live audio webcast of the presentation can be accessed here or by visiting Events & Presentations in the Investor Relations section of the Supernus Pharmaceuticals website at www.supernus.com. An archived replay of the webcasts will be available for 60 days on the Company's website following the conference.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Our diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel product candidates for CNS disorders.
For more information, please visit www.supernus.com.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company's ability to sustain and increase its profitability; the Company's ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company's corporate strategy; the Company's future financial performance and projected expenditures; the Company's ability to increase the number of prescriptions written for each of its products, and the products of its subsidiaries; the Company's ability to increase its net revenue from its products, and the products of its subsidiaries; the Company's ability to commercialize its products, and the products of its subsidiaries; the Company's ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company's product research and development activities, including the timing and progress of the Company's clinical trials, and projected expenditures; the Company's ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company's product candidates; the Company's ability to protect its intellectual property and the intellectual property of its subsidiaries and operate its business without infringing upon the intellectual property rights of others; the Company's expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company's product candidates; the accuracy of the Company's estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company's ability to increase its manufacturing capabilities for its products and product candidates; the Company's projected markets and growth in markets; the Company's product formulations and patient needs and potential funding sources; the Company's staffing needs; changes to laws and regulations applicable to our industry, the impact of macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs; and other risk factors set forth from time to time in the Company's filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.
CONTACTS:
Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
(301) 838-2591
or
INVESTOR CONTACT:
Peter Vozzo
ICR Healthcare
(443) 213-0505
peter.vozzo@icrhealthcare.com
